EirGen Pharma Product Eir-116 Passes Bioequivalence Study in EU

EirGen Pharma are pleased to announce that Eir-116, a product which was developed as a treatment for chronic (long-term) hepatitis B has successfully passed its Bioequivalence Study in EU.